Skip to main content
. 2022 Jul 14;6:e2100512. doi: 10.1200/PO.21.00512

FIG 1.

FIG 1.

Kaplan-Meier curves for the differences in median TTF between patients with detectable and undetectable ctDNA at (A) baseline, (B) mid-treatment, and (C) first restaging. Detectable ctDNA was associated with a shorter median TTF than undetectable ctDNA at baseline (11 weeks; 95% CI, 9.1 to 12.9 v 16 weeks; 95% CI, 12.3 to 19.7, respectively; P = .001), mid-treatment (10 weeks; 95% CI, 7.9 to 12.1 v 18 weeks; 95% CI, 10.5 to 25.5, respectively; P < .001), and first restaging (10 weeks; 95% CI, 8.5 to 11.5 v 24 weeks; 95% CI, 17.3 to 30.7, respectively; P < .001). ctDNA, circulating tumor DNA; TTF, time-to-treatment failure.